Login to Your Account

What Next for Qnexa?

FDA's Request Shakes Up Vivus Stock, Qnexa Timeline

By Tom Wall

Monday, January 24, 2011
A week after Vivus Inc. CEO Leland Wilson praised the FDA during a breakout session at the J.P. Morgan Healthcare conference, the agency's request for more data about the incidence of birth defects in children born to women using topiramate, a component in obesity treatment Qnexa (phentermine/topiramate), shook the company's stock and plans for August FDA approval and a late 2011 launch.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription